Tiziana Life Sciences Ltd (NASDAQ:TLSA)
| Market Cap | 62.15M-43.9% |
| Revenue (ttm) | 0 |
| Net Income | -18.43M+10.0% |
| EPS | -0.32+17.3% |
| Shares Out | 63.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 245,449 |
| Open | 0.99 |
| Previous Close | 0.99 |
| Day's Range | 0.95 - 0.99 |
| 52-Week Range | 0.87 - 2.35 |
| Beta | 0.46 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Sep 18, 2026 |
About TLSA
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TLSA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TLSA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TLSA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TLSA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TLSA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TLSA from public contracts
Source: USAspending.gov
TLSA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TLSA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score